

Photocure ASA 2nd Quarter 2023 Results

August 9, 2023

Dan Schneider, President and CEO

Erik Dahl, CFO

David Moskowitz, VP Investor Relations



THE
BLADDER CANCER
COMPANY

Disclaimer

By reading this company presentation (the "Presentation") or attending any meeting or oral presentation held in relation thereto, you (the "Recipient") agree to be bound by the following terms, conditions and limitations.

The Presentation has been produced by Photocure ASA (the "Company") for information purposes only and does not in itself constitute, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction. The distribution of this Presentation may be restricted by law in certain jurisdictions, and the Recipient should inform itself about, and observe, any such restriction. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction.

The Recipient acknowledges that it will be solely responsible for its own assessment of the Company, the market and the market position of the Company and that it will conduct its own analysis and be solely responsible for forming its own view of the potential future performance of the Company's business. The Company shall not have any liability whatsoever (in negligence or otherwise) arising directly or indirectly from the use of this Presentation or its contents, including but not limited to any liability for errors, inaccuracies, omissions or misleading statements in this Presentation, or violation of distribution restrictions.

The Presentation will be used during an oral presentation and is therefore not a complete summary of the presentation held. Further, it is not the intention to provide, and the Recipient may not rely on the Presentation as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects. Several factors could adversely affect the business, legal or financial position of the Company or the value of its securities. For a further description of other relevant risk factors, we refer to the Company's annual report for 2022. Should one or more of these or other risks and uncertainties materialize, actual results may vary significantly from those described in this Presentation.

This Presentation contains certain forward-looking statements relating to inter alia the business, financial performance and results of the Company and the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts. Any forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources, are solely opinions and forecasts and are subject to risks, uncertainties and other factors that may cause actual results and events to be materially different from those expected or implied by the forward-looking statements. The Company cannot provide any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of opinions expressed in this Presentation or the actual occurrence of forecasted developments.

This Presentation speaks as at the date set out on herein. Neither the delivery of this Presentation nor any further discussions of the Company shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The Company does not assume any obligation to update or revise the Presentation or disclose any changes or revisions to the information contained in the Presentation (including in relation to forward-looking statements).

This Presentation is subject to Norwegian law, and any dispute arising in respect of this Presentation is subject to the exclusive jurisdiction of Norwegian courts.



2nd Quarter 2023 Highlights:

Sequential growth from Q1' 2023 recovery despite phase down of flexible BLC

+16% Revenue growth

Units up 2% excl. German stocking prior year

Hexvix/Cysview revenue up 9% from Q1'23; units up 6% sequentially

Installed base of blue light (U.S.):

- 8 new Saphira™ towers in Q2
- 5 upgrades from existing accounts
- 40 quotes, 12 new Saphira™ purchase orders so far in Q3

Ongoing challenges:

- phase down of flex BLC utilization
- staffing shortages slowly resolving

EBITDA NOK 23.4 million

NOK 6.1M ex-BD exp. & Asieris payment

Asieris Cevira milestone

NOK 26.9 million

OPEX mostly level excl. FOREX & BD last 7 quarters; Continued investment behind Hexvix/Cysview

Biz Dev expense NOK 9.6 million

Positive cash flow in Q2

NOK 259 million in cash and equivalents; term debt fully paid off in Q2 2023

Key news and events

AUA 2023: Nordic registry data & multiple scientific programs focusing on BLC® (April/May)

2 urology journal publications: reduced recurrence risk & detection of CIS with BLC® (May)

Asieris completes Hexvix phase III study enrolment in China (July)

Citizen's Petition* to re-classify BLC equipment: process ongoing

Segment Trends

North America and Europe markets




Sequential Growth Achieved in Both Territories



THE
BLADDER CANCER
COMPANY


Q1 & Q2 Hexvix/Cysview Unit Sales by Region (Last 3 Years)

North America



Europe

(*German hospital stocking in Q2 2022)




Q2 2023 Trends in North America

- **Q2 revenues & in-market unit sales increased 19% & 3%, respectively; Unit sales rose 4% sequentially Q2'23/Q1'23;** Higher unit sales in new and upgraded Saphira™ accounts were partially offset by the phase down of flexible BLC usage
- **Continued expansion of blue light tower installed base:** 8 new Saphira™ installations, 5 upgrades in Q2 (40 quotes, 12 new tower POs so far in Q3)
- **Demand for new blue light equipment remains strong:** New Tower pipeline remains robust, Karl Storz discount programs (July 1 – Sept. 30) expected to accelerate Saphira™ adoption
- **Strong advocacy for Citizen's Petition continues** for the reclassification of blue light equipment; if approved, would enable an expedited pathway to expand the number of capital equipment manufacturers in the U.S.
 - Public comments by KOLs, BCAN (U.S. Patient Advocacy), Equipment Manufacturers, Health systems and others
 - Flex tower discontinuation highlights the need for BLC reclassification
 - Photocure customers continue to voice support for reclassification
 - FDA gathering information: Karl Storz and FDA have had correspondence, Photocure requested & participated in informational Q-Sub meeting with the agency



Karl Storz SAPHIRA™ Blue Light System



April 2023: Satellite Symposium + AUA congress booth


Saphira™ now 28% of rigid BLC installed base in U.S.

13 Installations in Q2 2023: 8 new account placements & 5 upgrades




THE
BLADDER CANCER
COMPANY

Annual New BLC Tower Installations (Rigid Only)



Cumulative Installed Base in U.S. (Rigid Only)



New Account Tower Installations
 Q3 2022: 10 installations (6 Rigid & 4 Flex)
 Q4 2022: 31 installations (24 Rigid & 7 Flex)
 Q1 2023: 18 installations (Rigid only)
Q2 2023: 8 installations (Rigid only)

93 Saphira™ towers installed since Q4 2022 launch; 48 New & 45 Upgrades

*2012 – 17 of the 23 installations were converted clinical sites upon Cysview approval

Q2 2023 Trends in Europe

- **Q2 revenues increased 14%, unit sales off 5% (up 0.5% ex-stocking); Unit sales rose 6% sequentially Q2'23/Q1'23;** Positive effects of price increases and FX outweighed significant stocking by German hospitals in the 2022 comparable period and further unit sales decline in Denmark..
- **2023 is first year where access is fully open since re-acquiring the territory in Oct. 2020** (focused on the 80% of existing accounts that are underpenetrated)
- **Image quality upgrades remains a key initiative in 2023**
Europe impacted overall by slow delivery of Saphira™ equipment but good pipeline
- **Blue light gaining traction in urology community**
Increasing KOL support broadly, high visibility at EAU,
Additional data strengthens EAU guidelines
- **Photocure 2023 Bladder Cancer Bus Tour:** high demand from German hospitals interested in BLC



EAU 2023: Urologist Interviews for HCP education videos on the Photocure booth

Growth acceleration in Europe expected



THE
BLADDER CANCER
COMPANY

Q2 2023

Established Markets

Nordic (excl. DK)/DACH
26% to 58% range of
penetration

- **Continuous Investment in Commercial Excellence**
- Good Penetration, Guidelines & Procedure Funding
- Germany/Austria (70% of EU unit sales) consistently increasing market share YoY
- Addressing DK situation pulling down Nordics

- **Steady Growth in DACH continues**
- **Outdated equipment in Nordics; upgrade anticipated H1 2024**

Priority Growth Markets

France, UK, Italy, Be/Ne
2% to 14% penetration


- **Active Pipeline for Image Quality Upgrades (Reactivation) & New Installations**
- Mostly good installed base of equipment but dated, underpenetrated, clinical practice & awareness differs
- Stabilized sales during the pandemic after years of decline before re-acquisition

- **Be/Ne first markets to move from stabilization to growth, other markets good pipeline but capital equipment delivery delays**

Untapped EU Markets

Spain, Poland, Baltics,
Czech Rep, Hungary, Ireland,
Greece, Portugal:
~0% penetration

- **Evaluating key launch factors in each territory:**
 - Availability of capital equipment
 - Local treatment guidelines
 - KOL engagement
 - Coverage/reimbursement
 - Decision on direct/distribution strategy



Q2 Financials

Consolidated Income Statement Second Quarter 2023



THE
BLADDER CANCER
COMPANY

<i>Amounts in NOK million</i>	Q2 '23	Q2 '22	Change	YTD '23	YTD '22	Change
Hexvix/Cysview Revenue	115.9	99.9	16%	221.8	181.2	22%
Other Revenue	28.4	0.7		28.7	1.0	
Total Revenue	144.3	100.6	44%	250.6	182.2	38%
Gross Profit	137.4	95.3	44%	237.2	170.9	39%
Operating Expenses excl BD	-104.4	-88.8	18%	-205.3	-175.3	17%
Business Development Expenses	-9.6	-5.1		-9.7	-8.0	
EBITDA – excluding BD	33.0	6.5		31.9	-4.5	
EBITDA – including BD	23.4	1.4		22.2	-12.5	
Depreciation & Amortization	-6.6	-6.0		-13.1	-12.0	
EBIT	16.8	-4.6		9.2	-24.5	
Net Financial Items	-4.9	-4.5		-7.3	-11.8	
Earnings before Tax	12.0	-9.1		1.9	-36.3	
Tax Expenses	-7.6	-9.4		-9.3	-4.1	
Net earnings	4.3	-18.5		-7.4	-40.4	

Revenue

- Q2 total revenue increased YoY 44%, driven by Hexvix/Cysview and a milestone payment from Asieris
- Q2 Hexvix/Cysview revenue increased 16% vs. last year, driven by price and FX. Sequential revenue growth of 9% from Q1
 - Consolidated volume impacted negatively by the phase down of Cysview usage in the flexible BLC setting as well as German hospital stocking last year ahead of a July 2022 price increase

Operating Expenses

- Q2 operating expenses excluding business development costs increased 18% YoY, mainly due to FX and inflation
- Operating expenses within business development projects relate to life cycle management for Hexvix/Cysview

EBITDA

- Q2 EBITDA including business development expenses improved NOK 22.0 million YoY, driven by revenue growth including milestone payments

Segment Performance Second Quarter 2023

North America Segment

<i>Amounts in NOK million</i>	Q2 '23	Q2 '22	Change	YTD '23	YTD '22	Change
Total revenues	46.2	38.7	19%	88.3	69.2	28%
Gross profit	44.8	37.7	19%	85.5	67.0	28%
<i>% of revenue</i>	<i>97%</i>	<i>97%</i>		<i>97%</i>	<i>97%</i>	
Direct costs	-44.8	-40.2	12%	-88.4	-78.2	13%
Contribution ⁽¹⁾	0.0	-2.5		-2.8	-11.1	
EBITDA, excl BD	-10.3	-11.1		-22.0	-28.5	
<i>% of revenue</i>	<i>-22%</i>	<i>-29%</i>		<i>-25%</i>	<i>-41%</i>	

- Q2 revenue growth 19% driven by volume, price increases and FX.
 - In-market unit sales increased 3%, USD appreciated 14%, price increase 3% in US
- Q2 direct costs as planned in local currencies
- Contribution improved NOK 2.5 million YoY driven by revenue

Europe Segment

<i>Amounts in NOK million</i>	Q2 '23	Q2 '22	Change	YTD '23	YTD '22	Change
Total revenues	69.7	61.1	14%	133.3	111.6	19%
Gross profit	65.2	57.3	14%	123.7	103.0	20%
<i>% of revenue</i>	<i>93%</i>	<i>94%</i>		<i>93%</i>	<i>92%</i>	
Direct costs	-27.6	-26.3	5%	-56.6	-47.9	18%
Contribution ⁽¹⁾	37.6	31.0		67.2	55.1	
EBITDA, excl BD	19.5	16.0		33.2	24.2	
<i>% of revenue</i>	<i>28%</i>	<i>26%</i>		<i>25%</i>	<i>22%</i>	

- Q2 revenue increased 14% YoY. EUR appreciated 16%
 - In-market unit sales decreased 5% YoY; excluding German stocking effect in 2022 volume mostly level with prior year
- Expenses were driven by phasing of activities and FX
- Contribution improved NOK 6.6 million YoY, driven by higher revenue

Cash Flow & Balance Sheet Second Quarter 2023

<i>Amounts in NOK million</i>	Q2 '23	Q2 '22	YTD '23	YTD '22
Operations Cash Flow	29.1	-1.9	20.0	-24.1
Earnings before tax	12.0	-9.1	1.9	-36.3
Depreciation & amortization	6.5	6.0	13.1	12.0
Working capital	-1.1	-11.6	-11.7	-20.1
Other	11.7	12.8	16.7	20.3
Investments Cash Flow	0.1	-2.5	0.7	-2.0
Financing Cash Flow	-16.3	-8.0	-29.8	-23.8
Net Change in Cash	12.9	-12.4	-9.1	-49.8

<i>Amounts in NOK million</i>	31.06.23	31.12.22
Non-current assets	345.4	360.8
Inventory & receivables	102.2	90.2
Cash & short-term deposits	258.9	268.1
Equity	467.5	462.7
Long-term liabilities	162.1	167.1
Current liabilities	77.0	89.2
Total balance	706.6	719.0

Cash Flow

- Net cash flow from operations in Q2 NOK 29.1 million, mainly driven by milestones received
- Net cash flow from financing NOK -16.3 million includes loan repayment of NOK 6.3 million and earnout payments of NOK 8.1 million
 - Term loan is fully repaid
- Net cash flow in Q2 NOK 12.9 million, cash balance end of Q2 NOK 258.9 million

Financial position

- Non-current assets includes intangibles and goodwill from Ipsen transaction totaling NOK 264.9 million
- Long-term liabilities includes deferred Ipsen earnout totaling NOK 130.3 million
- Equity NOK 467.5 million, 66% of total assets

Summary



Summary of Q2 results

- 16% rev. growth/+2% unit sales excl. German stocking; 9% sequential rev. growth despite U.S. Flex phase down
- 13 Saphira™ towers installed in U.S. (8 new, 5 upgrades); 40 quotes/12 new BLC tower POs so far in Q3
- Saphira™ now 28% of rigid towers in U.S.; New technology cycle, strong pipeline, KS discounts driving adoption
- EBITDA of NOK 23.4 million (NOK 33 million excl. BD); Commercial business EBITDA-positive in the quarter
- Term debt fully paid off in Q2, cash balance strong at NOK 259 million
- BLC awareness continues to rise in urology community, KOL support, and equipment/image quality upgrades
- Reiterated guidance; flex phase-down, remaining staffing shortages and strikes in EU remain challenges in 2023
- Potential re-classification of BLC equipment could “unlock” the market for Cysview in the U.S.

2023 Anticipated Milestones & Corporate Objectives



THE
BLADDER CANCER
COMPANY

- Deliver 65-75 Saphira™ installs, product revenue growth above 20%, and generate positive EBITDA in 2023
- Continue to grow the base of rigid blue light towers in North America, upgrade BLC® image quality throughout Europe, and pursue strategy to establish a durable solution for flexible BLC equipment globally
- Proactively support the Citizen's Petition for the U.S. FDA to reclassify BLC equipment from Class 3 to Class 2, potentially creating an expedited pathway for additional BLC manufacturers to enter the U.S. market
- Continue to geographically expand commercial business by penetrating untapped European markets, and through additional Hexvix® licensing agreements ROW
- Present/publish additional data from patient registries and other studies on the use of BLC® with Hexvix/Cysview
- Milestone events anticipated for partner, Asieris: Phase III data for Hexvix in China and Cevira® in H2 2023

Leading change in bladder cancer

Q&A

